1. Home
  2. SSKN vs AIM Comparison

SSKN vs AIM Comparison

Compare SSKN & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSKN
  • AIM
  • Stock Information
  • Founded
  • SSKN 1989
  • AIM 1966
  • Country
  • SSKN United States
  • AIM United States
  • Employees
  • SSKN N/A
  • AIM N/A
  • Industry
  • SSKN Medical/Dental Instruments
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SSKN Health Care
  • AIM Health Care
  • Exchange
  • SSKN Nasdaq
  • AIM Nasdaq
  • Market Cap
  • SSKN 13.5M
  • AIM 15.9M
  • IPO Year
  • SSKN 2005
  • AIM N/A
  • Fundamental
  • Price
  • SSKN $3.10
  • AIM $0.24
  • Analyst Decision
  • SSKN
  • AIM Strong Buy
  • Analyst Count
  • SSKN 0
  • AIM 2
  • Target Price
  • SSKN N/A
  • AIM $3.00
  • AVG Volume (30 Days)
  • SSKN 14.5K
  • AIM 220.7K
  • Earning Date
  • SSKN 11-13-2024
  • AIM 11-15-2024
  • Dividend Yield
  • SSKN N/A
  • AIM N/A
  • EPS Growth
  • SSKN N/A
  • AIM N/A
  • EPS
  • SSKN N/A
  • AIM N/A
  • Revenue
  • SSKN $32,729,999.00
  • AIM $201,000.00
  • Revenue This Year
  • SSKN $0.14
  • AIM N/A
  • Revenue Next Year
  • SSKN $12.67
  • AIM $1,086.80
  • P/E Ratio
  • SSKN N/A
  • AIM N/A
  • Revenue Growth
  • SSKN N/A
  • AIM 19.64
  • 52 Week Low
  • SSKN $2.51
  • AIM $0.21
  • 52 Week High
  • SSKN $7.00
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • SSKN 51.31
  • AIM 41.61
  • Support Level
  • SSKN $2.91
  • AIM $0.24
  • Resistance Level
  • SSKN $3.52
  • AIM $0.27
  • Average True Range (ATR)
  • SSKN 0.24
  • AIM 0.02
  • MACD
  • SSKN 0.00
  • AIM -0.00
  • Stochastic Oscillator
  • SSKN 45.45
  • AIM 24.25

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: